Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies

CONCLUSIONS: Radiogenomic immune biomarkers have the potential to provide early treatment options to patients with glioblastoma. Targeted immunotherapy, stratified by these biomarkers, has the potential to allow individualized neo-adjuvant precision treatment options in clinical trials. However, there are no prospective studies validating these biomarkers, and interpretation is limited due to study bias with little evidence of generalizability.PMID:38680991 | PMC:PMC11046988 | DOI:10.1093/noajnl/vdae055

Source: Adv Data - April 29, 2024 Category: Epidemiology Authors: Prajwal Ghimire Ben Kinnersley Golestan Karami Prabhu Arumugam Richard Houlston Keyoumars Ashkan Marc Modat Thomas C Booth Source Type: research